Emerging treatment options for extraintestinal manifestations in IBD

被引:67
作者
Greuter, Thomas [2 ,3 ]
Rieder, Florian [4 ]
Kucharzik, Torsten [5 ]
Peyrin-Biroulet, Laurent [6 ]
Schoepfer, Alain M. [7 ,8 ]
Rubin, David T. [9 ]
Vavricka, Stephan R. [1 ,2 ]
机构
[1] Gastroenterol & Hepatol Ctr, Zurich, Switzerland
[2] Univ Hosp Zurich, Dept Gastroenterol & Hepatol, Zurich, Switzerland
[3] GZO Zurich Reg Hlth Ctr, Dept Internal Med, Wetzikon, Switzerland
[4] Cleveland Clin, Digest Dis & Surg Inst, Div Gastroenterol Hepatol & Nutr, Cleveland, OH 44106 USA
[5] Klinikum Lueneburg, Div Gastroenterol & Hepatol, Luneburg, Germany
[6] Univ Henri Poincare 1, Univ Hosp Nancy, Dept Hepatogastroenterol, Inserm U954, Vandoeuvre Les Nancy, France
[7] Univ Hosp Lausanne CHUV, Div Gastroenterol & Hepatol, Lausanne, Switzerland
[8] Univ Lausanne, Lausanne, Switzerland
[9] Univ Chicago, Ctr Inflammatory Bowel Dis, Chicago, IL 60637 USA
基金
瑞士国家科学基金会;
关键词
arthritis; IBD clinical; TNF;
D O I
10.1136/gutjnl-2020-322129
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Extraintestinal manifestations (EIMs) are frequently observed in IBDs and contribute considerably to morbidity and mortality. They have long been considered a difficult to treat entity due to limited therapy options, but the increasing use of anti-tumour necrosis factors has dramatically changed the therapeutic approach to EIM in recent years. Newly emerging therapies such as JAK inhibitors and anti-interleukin 12/23 will further shape the available armamentarium. Clinicians dealing with EIMs in everyday IBD practice may be puzzled by the numerous available biological agents and small molecules, their efficacy for EIMs and their potential off-label indications. Current guidelines on EIMs in IBD do not include treatment algorithms to help practitioners in the treatment decision-making process. Herein, we summarise knowledge on emerging biological treatment options and small molecules for EIMs, highlight current research gaps, provide therapeutic algorithms for EIM management and shed light on future strategies in the context of IBD-related EIMs.
引用
收藏
页码:796 / 802
页数:7
相关论文
共 86 条
  • [1] Characteristics and Treatment of Pyoderma Gangrenosum in Inflammatory Bowel Disease
    Argueelles-Arias, F.
    Castro-Laria, L.
    Lobaton, T.
    Aguas-Peris, M.
    Rojas-Feria, M.
    Barreiro-de Acosta, M.
    Soto-Escribano, P.
    Calvo-Moya, M.
    Ginard-Vicens, D.
    Chaparro-Sanchez, M.
    Hernandez-Duran, M.
    Castro-Senosiain, B.
    Fernandez-Villaverde, A.
    Garcia-Sanchez, V.
    Dominguez-Munoz, E.
    Caunedo-Alvarez, A.
    Herrerias-Gutierrez, J. M.
    [J]. DIGESTIVE DISEASES AND SCIENCES, 2013, 58 (10) : 2949 - 2954
  • [2] Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial
    Bachelez, Herve
    van de Kerkhof, Peter C. M.
    Strohal, Robert
    Kubanov, Alexey
    Valenzuela, Fernando
    Lee, Joo-Heung
    Yakusevich, Vladimir
    Chimenti, Sergio
    Papacharalambous, Jocelyne
    Proulx, James
    Gupta, Pankaj
    Tan, Huaming
    Tawadrous, Margaret
    Valdez, Hernan
    Wolk, Robert
    [J]. LANCET, 2015, 386 (9993) : 552 - 561
  • [3] Barreiro-de-Acosta M, 2012, REV ESP ENFERM DIG, V104, P468, DOI 10.4321/s1130-01082012000900004
  • [4] Bernstein CN, 2001, AM J GASTROENTEROL, V96, P1116
  • [5] The clustering of other chronic inflammatory diseases in inflammatory bowel disease: A population-based study
    Bernstein, CN
    Wajda, A
    Blanchard, JF
    [J]. GASTROENTEROLOGY, 2005, 129 (03) : 827 - 836
  • [6] Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial
    Brooklyn, TN
    Dunnill, MGS
    Shetty, A
    Bowden, JJ
    Williams, JDL
    Griffiths, CEM
    Forbes, A
    Greenwood, R
    Probert, CS
    [J]. GUT, 2006, 55 (04) : 505 - 509
  • [7] Incidence of Immune-Mediated Inflammatory Diseases Among Patients With Inflammatory Bowel Diseases in Denmark
    Burisch, Johan
    Jess, Tine
    Egeberg, Alexander
    [J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2019, 17 (13) : 2704 - +
  • [8] Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial
    Burmester, Gerd R.
    Blanco, Ricardo
    Charles-Schoeman, Christina
    Wollenhaupt, Juergen
    Zerbini, Cristiano
    Benda, Birgitta
    Gruben, David
    Wallenstein, Gene
    Krishnaswami, Sriram
    Zwillich, Samuel H.
    Koncz, Tamas
    Soma, Koshika
    Bradley, John
    Mebus, Charles
    [J]. LANCET, 2013, 381 (9865) : 451 - 460
  • [9] Infliximab for Inflammatory Bowel Disease in Denmark 1999-2005: Clinical Outcome and Follow-Up Evaluation of Malignancy and Mortality
    Caspersen, Sarah
    Elkjaer, Margarita
    Riis, Lene
    Pedersen, Natalia
    Mortensen, Christian
    Jess, Tine
    Sarto, Pernille
    Hansen, Tanja S.
    Wewer, Vibeke
    Bendtsen, Flemming
    Moesgaard, Flemming
    Munkholm, Pia
    [J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2008, 6 (11) : 1212 - 1217
  • [10] Vedolizumab Treatment in Extra-Intestinal Manifestations in Inflammatory Bowel Disease: A Systematic Review
    Chateau, Thomas
    Bonovas, Stefanos
    Le Berre, Catherine
    Mathieu, Nicolas
    Danese, Silvio
    Peyrin-Biroulet, Laurent
    [J]. JOURNAL OF CROHNS & COLITIS, 2019, 13 (12) : 1569 - 1577